98 studies found for:    "neurofibromatosis type 2" OR "neurofibromatosis"
Show Display Options
RSS Create an RSS feed from your search for:
"neurofibromatosis type 2" OR "neurofibromatosis"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Vestibular Schwannoma;   Neurofibromatosis Type 2
Intervention: Drug: Endostatin
2 Recruiting Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Vestibular Schwannomas
Intervention: Drug: Axitinib
3 Active, not recruiting Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Neurofibromatosis 2;   Vestibular Schwannoma
Intervention: Drug: Lapatinib
4 Completed Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
Conditions: Acoustic Schwannoma;   Neurofibromatosis Type 2
Interventions: Biological: bevacizumab;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
5 Active, not recruiting Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
Condition: Neurofibromatosis 2
Intervention: Drug: RAD001
6 Unknown  Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Condition: Neurofibromatosis Type II
Intervention: Drug: Everolimus (RAD001) , Afinitor®
7 Recruiting Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Conditions: Neurofibromatosis Type 2;   Neuroma, Acoustic
Intervention: Drug: RAD001, everolimus
8 Suspended PTC299 for Treatment of Neurofibromatosis Type 2
Condition: Neurofibromatosis 2
Intervention: Drug: PTC299
9 Recruiting Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Progressive Vestibular Schwannomas
Intervention: Drug: Bevacizumab
10 Recruiting Neurofibromatosis (NF) Registry Portal
Conditions: Neurofibromatosis 1;   Neurofibromatosis 2;   Schwannomatosis
Intervention:
11 Completed An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
Condition: Neurofibromatosis 2
Intervention: Device: Penetrating auditory brainstem implant
12 Active, not recruiting Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Conditions: Acoustic Schwannoma;   Adult Anaplastic Meningioma;   Adult Ependymoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Meningeal Hemangiopericytoma;   Adult Papillary Meningioma;   Neurofibromatosis Type 1;   Neurofibromatosis Type 2;   Recurrent Adult Brain Tumor
Intervention: Biological: bevacizumab
13 Completed Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
Condition: Neurofibromatosis 2
Intervention: Device: Multichannel Auditory Brain Stem Implant
14 Recruiting Concentration and Activity of Lapatinib in Vestibular Schwannomas
Conditions: Vestibular Schwannoma;   NF2;   Neurofibromatosis 2;   Acoustic Neuroma;   Auditory Tumor
Intervention: Drug: lapatinib
15 Active, not recruiting Natural History Study of Patients With Neurofibromatosis Type 2
Conditions: Spinal Cord Disease;   Intracranial Central Nervous System Disorder;   Neurologic Disorders;   Brain Neoplasms
Intervention:
16 Active, not recruiting Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Conditions: Neoplasms;   Nervous System Disease;   Vestibular Disease
Intervention:
17 Recruiting Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Conditions: Neurofibromatosis Type 2;   Vestibular Schwannomas;   Meningiomas
Intervention: Drug: RAD001 10mg p.o. daily
18 Unknown  NF2 Natural History Consortium
Conditions: Schwannoma, Vestibular;   Neurofibromatosis 2;   Meningioma
Intervention:
19 Completed Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I
Conditions: Neurofibromatosis Type 1;   Von Recklinghausen Disease;   NF1
Intervention:
20 Active, not recruiting Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Conditions: Neurofibromatosis;   NF1;   Neurofibromas
Intervention: Drug: Tasigna

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years